CEROW CERO THERAPEUTICS HOLDINGS, INC.: institutional ownership and insider trading
3 funds reported holding $11.0K of CERO THERAPEUTICS HOLDINGS, INC. in their latest 13F filings; in Q2 2026 funds net bought $0, with 0 new positions and 0 funds selling out; over the last 12 months insiders bought $0 and sold $0 on the open market.
CEROW revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$1.03M, EPS -0.70
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.89M, EPS -0.20
- Quarter ended Dec 31, 2025: revenue n/a, net income −$4.54M
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.86M, EPS -9.10
Largest institutional holders of CEROW
- Clear Street Derivatives LLC — $6.38K
- CLEAR STREET LLC — $4.61K
- Ancora Advisors LLC — $4
Recent CEROW insider trades
- Dec 13, 2024: YK Bioventures Opportunities GP I, LLC sold 5,957,250 shares ($400K)
- Dec 10, 2024: YK Bioventures Opportunities GP I, LLC sold 3,658,364 shares ($383K)
5%+ owners
- Brian G. Atwood: 9.9% (Schedule 13D/A, filed Apr 4, 2025)
Who owns the most CEROW stock?
The largest institutional holders of CERO THERAPEUTICS HOLDINGS, INC. in the latest 13F filings are Clear Street Derivatives LLC ($6.38K), CLEAR STREET LLC ($4.61K), Ancora Advisors LLC ($4).
Are insiders buying or selling CEROW?
No open-market insider buys or sells of CERO THERAPEUTICS HOLDINGS, INC. were reported in the last 12 months.